AAPS 2026: How Skin Laboratory Testing Supports Topical and Mucoadhesive Drug Development
By Kyle Loethen
AAPS 2026: How Skin Laboratory Testing Supports Topical and Mucoadhesive Drug Development
Topical Formulation Development: Why Dermatology Drug Development Demands Specialized CDMO Expertise
By Kyle Loethen
IVRT and IVPT Testing: Turning Skin Performance Data Into Better Topical Drug Development Decisions
By Kyle Loethen
Estrogen Manufacturing: It Takes the Right Chemistry
By Kyle Loethen
Meet the Evolving CPL at CPHI Milan: More Capabilities, More Expertise, More Reasons to Talk
By Kyle Loethen
Seven Important Questions Every Pharmaceutical Company Should Ask Before Choosing a CDMO
By Kyle Loethen
Testosterone Manufacturing Is Not the Place to Experiment: Why Experience Matters When Choosing a CDMO
By Kyle Loethen
The Hidden Reasons CDMO Projects Go Off Track Before Manufacturing Ever Begins
By Kyle Loethen
Meet CPL at the Rutgers Annual Innovations in Dermatological Sciences Conference: Why Commercial Thinking Matters in Topical Drug Development
By Kyle Loethen
Bridging the Hidden Gap: Why Sponsors Need a Guided Handoff from Development to Manufacturing
By Kyle Loethen